Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer

University of Calgary

$65,000.00

Enhancing T cell-based treatments in breast cancer using engineered type 2 innate lymphoid cells

FY 2023-24

Summary
One Canadian succumbs to breast cancer every 90 minutes. New treatments using T cells, a subset of white blood cells, have shown promise in cancer therapy. However, only a fraction of patients suffering from breast cancer has benefited from these therapies. This proposal seeks to understand how type 2 innate lymphoid cells (ILC2s), another type of white blood cells, may improve the efficacy of T cell therapies. Our previous work identified ILC2s as a cell type involved in cancer control. This project aims to i) manipulate ILC2s to empower them with superior anti-tumour function and ii) test their efficacy in combination with T cell therapy in cells and animals. Collectively, our findings will define the therapeutic potential of ILC2s in combination with T cell treatment with the ultimate goal of improving breast cancer patient outcomes.
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
516992
Name
Jacquelot Nicolas
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Enhancing T cell-based treatments in breast cancer using engineered type 2 innate lymphoid cells
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
One Canadian succumbs to breast cancer every 90 minutes. New treatments using T cells, a subset of white blood cells, have shown promise in cancer therapy. However, only a fraction of patients suffering from breast cancer has benefited from these therapies. This proposal seeks to understand how type 2 innate lymphoid cells (ILC2s), another type of white blood cells, may improve the efficacy of T cell therapies. Our previous work identified ILC2s as a cell type involved in cancer control. This project aims to i) manipulate ILC2s to empower them with superior anti-tumour function and ii) test their efficacy in combination with T cell therapy in cells and animals. Collectively, our findings will define the therapeutic potential of ILC2s in combination with T cell treatment with the ultimate goal of improving breast cancer patient outcomes.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Jacquelot, Nicolas
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~